Genmab

Recent news

• Rating change
  A Quick Look at Today's Ratings for Genmab(GMAB.US), With a Forecast Between $40 to $40
  Market Newswire · 2026/6/30
• Rating change
  William Blair Maintains Genmab(GMAB.US) With Buy Rating
  Market Newswire · 2026/8/12
• Rating change
  Guggenheim Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $40
  Market Newswire · 2026/5/26
• Rating change
  Wolfe Research Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $32
  Market Newswire · 2026/6/15
• Rating change
  Wells Fargo Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $40
  Market Newswire · 2026/6/2
• Rating change
  Wolfe Research Initiates Genmab(GMAB.US) With Buy Rating, Announces Target Price $32
  Market Newswire · 2026/3/27
• Rating change
  H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Cuts Target Price to $38
  Market Newswire · 2026/4/30
• Rating change
  Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Cuts Target Price to $33
  Market Newswire · 2026/5/8
• Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $33
  Market Newswire · 2026/7/23
• Rating change
  Analysts Offer Insights on Healthcare Companies: Genmab (GMAB) and Hinge Health, Inc. Class A (HNGE)
  TipRanks · 2026/6/30
• Truist Financial Maintains Genmab(GMAB.US) With Buy Rating
  Market Newswire · 2026/8/12
• A Quick Look at Today's Ratings for Genmab(GMAB.US), With a Forecast Between $35 to $43
  Market Newswire · 2026/8/8
• Rating change
  Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Definitive Healthcare Corp (DH) and Atai Beckley N.V. (ATAI)
  TipRanks · 2026/8/12
• TD Cowen Upgrades Genmab(GMAB.US) to Buy Rating, Raises Target Price to $43
  Market Newswire · 2026/7/22
• Rating change
  Analysts Are Bullish on Top Healthcare Stocks: Genmab (GMAB), Caris Life Sciences, Inc. (CAI)
  TipRanks · 2026/5/12
• Rating change
  H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $40
  Market Newswire · 2026/7/2
• Rating change
  Truist Financial Maintains Genmab(GMAB.US) With Buy Rating, Cuts Target Price to $40
  Market Newswire · 2026/5/27
• Rating change
  TD Cowen Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $32
  Market Newswire · 2026/7/13
• Rating change
  H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $38
  Market Newswire · 2026/6/23
• H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $40
  Market Newswire · 2026/9/14

Headlines are aggregated automatically and are not independently verified or edited by our team.